wegovy

Amgen Inc. (NASDAQ:AMGN) has kicked off two crucial phase three trials for MariTide, its investigational weight loss injection. This move marks a significant step in the company’s pursuit to break into the growing market for obesity drugs. What Happened: The MARITIME program, the drug...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with the Senate Finance Committee. While Kennedy’s tone in each back-and-forth varied, depending on the senator, it was...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

Novo Nordisk A/S (NYSE:NVO) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped obesity drug, CagriSema. To put the move in perspective, the only steeper plunge in the Danish pharma...

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's (NASDAQ:AMGN) new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight. But when up against the current titans — Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/...

The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordisk A/S (NYSE:NVO) has faced backlash for the steep prices of Wegovy and Ozempic, two popular drugs...

Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects. What Happened: The Danish pharmaceutical giant is contending with rivals like Eli Lilly & Co...

Hims & Hers Health Inc. (NYSE:HIMS) shares fell Wednesday following an FDA update listing Novo Nordisk’s (NYSE:NVO) diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here’s what you need to know. What Happened: A report from the FDA...

Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper alternatives have been under scrutiny due to potential safety risks and lack of FDA approval....

Novo Nordisk A/S (NYSE:NVO) just hit a technical red flag — a Death Cross. Chart created using Benzinga Pro For those uninitiated, this bearish signal occurs when a stock's 50-day moving average drops below its 200-day moving average, hinting that more downside could be ahead. However, Novo...

Viking Therapeutics Inc. (NASDAQ:VKTX) is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735. As...

The Federal Reserve's preferred measure of inflation, the personal consumption expenditures index, grew less than economists expected in August at 2.2% year-over-year. The data comes on the heels of the Federal Reserve's 0.5% interest rate cut issued Sept. 18, the first in more than four years....

Novo Nordisk A/S (NYSE:NVO) is under mounting political pressure over the high U.S. prices of its blockbuster weight-loss drugs, Ozempic and Wegovy, as the race for the White House heats up. The pricing disparity between the U.S. and other international markets has drawn sharp criticism from...

Novo Nordisk A/S (NYSE:NVO) will consider ways to help patients get affordable prescriptions for weight loss drugs, CEO Lars Fruergaard Jorgensen told members of the U.S. Congress on Wednesday when asked if his company would lower U.S. prices for Ozempic and Wegovy. Jorgensen sat before the Health...

Novo Nordisk's (NYSE:NVO) CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year. What Happened: Jorgensen is...